GHRS
GH Research PLCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$1.23B
P/E Ratio
—
EPS
$-0.79
Beta
1.00
52W High
$24.66
52W Low
$9.46
50-Day MA
$15.92
200-Day MA
$14.57
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About GH Research PLC
GH Research PLC is a clinical-stage biopharmaceutical company dedicated to developing innovative psilocybin-based therapies targeting psychiatric and neurodegenerative disorders. With a robust pipeline designed to address substantial unmet needs in mental health care, GH Research leverages a highly experienced team committed to pioneering advancements in this fast-evolving sector. The company's groundbreaking initiatives position it to redefine treatment paradigms and significantly improve patient outcomes, solidifying its potential as a leader in mental health therapeutics.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-60.60M |
| Operating Margin | 0.00% |
| Return on Equity | -21.00% |
| Return on Assets | -15.90% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $4.51 |
| Price-to-Book | 4.40 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -11.97 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $62.03M |
| Float | $22.80M |
| % Insiders | 26.78% |
| % Institutions | 75.01% |
Historical Volatility
HV 10-Day
107.52%
HV 20-Day
81.02%
HV 30-Day
77.87%
HV 60-Day
74.72%
HV Rank
62.3%
Volatility is currently expanding
Analyst Ratings
Consensus ($39.25 target)
3
Strong Buy6
BuyData last updated: 4/29/2026